Cargando…
Pharmacological and Biological Antiviral Therapeutics for Cardiac Coxsackievirus Infections
Subtype B coxsackieviruses (CVB) represent the most commonly identified infectious agents associated with acute and chronic myocarditis, with CVB3 being the most common variant. Damage to the heart is induced both directly by virally mediated cell destruction and indirectly due to the immune and aut...
Autores principales: | Fechner, Henry, Pinkert, Sandra, Geisler, Anja, Poller, Wolfgang, Kurreck, Jens |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6264230/ https://www.ncbi.nlm.nih.gov/pubmed/21989310 http://dx.doi.org/10.3390/molecules16108475 |
Ejemplares similares
-
Coxsackievirus B3—Its Potential as an Oncolytic Virus
por: Geisler, Anja, et al.
Publicado: (2021) -
Coxsackievirus B3 and adenovirus infections of cardiac cells are efficiently inhibited by vector-mediated RNA interference targeting their common receptor
por: Fechner, H, et al.
Publicado: (2007) -
A Novel Artificial MicroRNA Expressing AAV Vector for Phospholamban Silencing in Cardiomyocytes Improves Ca(2+) Uptake into the Sarcoplasmic Reticulum
por: Größl, Tobias, et al.
Publicado: (2014) -
Inhibition of coxsackievirus B3 by RNA interference (RNAi)
por: Kurreck, J, et al.
Publicado: (2006) -
Application Route and Immune Status of the Host Determine Safety and Oncolytic Activity of Oncolytic Coxsackievirus B3 Variant PD-H
por: Hazini, Ahmet, et al.
Publicado: (2021)